Benjamin Shaker - Sep 12, 2023 Form 4 Insider Report for agilon health, inc. (AGL)

Role
Chief Markets Officer
Signature
/s/ Steve Meetre, as Attorney-in-Fact
Stock symbol
AGL
Transactions as of
Sep 12, 2023
Transactions value $
-$533,811
Form type
4
Date filed
9/14/2023, 04:37 PM
Previous filing
Aug 16, 2023
Next filing
Mar 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGL Common Stock Options Exercise $71.1K +18.8K +23.57% $3.79* 98.3K Sep 12, 2023 Direct F1
transaction AGL Common Stock Sale -$338K -18.8K -19.08% $18.05 79.5K Sep 12, 2023 Direct F1, F2, F3
transaction AGL Common Stock Options Exercise $71.1K +18.8K +23.57% $3.79* 98.3K Sep 13, 2023 Direct F1
transaction AGL Common Stock Sale -$337K -18.8K -19.08% $18.00 79.5K Sep 13, 2023 Direct F1, F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGL Options (Right to buy) Options Exercise $0 -18.8K -5.53% $0.00 321K Sep 12, 2023 Common Stock 18.8K $3.79 Direct F5
transaction AGL Options (Right to buy) Options Exercise $0 -18.8K -5.85% $0.00 302K Sep 13, 2023 Common Stock 18.8K $3.79 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes restricted stock units.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan effective September 15, 2022.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.76 to $18.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.67 to $18.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 These options were granted on February 9, 2019, and became fully vested as of February 9, 2023.